In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.40M | $931.0M | 12.87% | +214.4K | 2026-06-30 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 5.58M | $619.0M | 8.56% | -- | 2026-06-30 |
| Jupiter Topco LLC | 5.19M | $575.0M | 7.95% | -- | 2026-06-30 |
| FMR LLC | 3.88M | $430.0M | 5.94% | -746.5K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.24M | $359.0M | 4.96% | +64.2K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.93M | $325.0M | 4.49% | +17.9K | 2026-06-30 |
| AMERICAN CENTURY COMPANIES INC | 2.82M | $312.0M | 4.32% | +1.04M | 2026-06-30 |
| STATE STREET CORP | 2.50M | $277.0M | 3.83% | +70.9K | 2026-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.90M | $211.0M | 2.92% | +983.6K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.84M | $204.0M | 2.82% | +75.4K | 2026-06-30 |
